Wang Qu
16 Papers
1 Citations
Wang Qu is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 11 publications.
Chat about Author
Papers
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements
Yongjun Sun,Wen Zhang,Xinyu Bi,Zhengqiang Yang,Yuan Tang,Liming Jiang,Feng Bi,Minshan Chen,Shu-Qun Cheng,Y. Choi,Yue Han,Ling Huang,Zhen Huang,Yuan Ji,Liqun Jia,Zhichao Jiang,Jing Jin,Zhengyu Jin,Xiao Li,Zhiyu Li,Jun Liang,Lianxin Liu,Yunpeng Liu,Yinying Lu,Shi-yong Lu,Qinghua Meng,Zuoxing Niu,Hongming Pan,Shukui Qin,Wang Qu,Guoliang Shao,Feng Shen,Tianqiang Song,Yan Song,Kaishan Tao,Ai-Ping Tian,Jinhua Wang,Wen-ling Wang,Zhe Yuan Wang,Liqun Wu,Feng Xiao,B. Xing,Jianming Xu,Huadan Xue,Dong Yan,Li Yang,Jianming Yang,Jingping Yun,Z. Zeng,Xuewen Zhang,Yanqiao Zhang,Ye Zhang,Jianjun Zhao,Jian-Guo Zhou,Xu Zhu,Ying-Ying Zou,Jiahong Dong,Jia Fan,Wan Yee Lau,Yan Sun,Jinming Yu,Hong Zhao,Aiping Zhou,Jianqiang Cai +63 more
TL;DR: Panel consensus statements for the appropriate use of new molecular -targeted drugs including doses, combination therapies, adverse reaction management as well as efficacy evaluation, and predictions for treatment of advanced HCC with evidence levels based on published data are presented, thereby providing an overview of molecular targeted therapies for healthcare professionals.
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial
Yong Li,Aiping Zhou,Shuoyan Liu,Ming He,Ke-Neng Chen,Ziqiang Tian,Ying Li,Jianjun Qin,Zhen Wang,Haiquan Chen,Hui Tian,Yue Yu,Wang Qu,Liyan Xue,Shun He,Shuhang Wang,Fenglong Bie,Guangyu Bai,Bolun Zhou,Zhaoyang Yang,Huiyao Huang,Yan-Man Fang,Benjamin Xiaoyi Li,Xiangrong Dai,Shugeng Gao,Jie He +25 more
TL;DR: In this article , the safety and efficacy of the neoadjuvant socazolimab, a novel PD-L1 inhibitor, in combination with nab-paclitaxel and cisplatin for locally advanced esophageal squamous cell carcinoma (ESCC) was evaluated.
14
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial
Wen Zhang,Haitao Zhou,Jun Jiang,Yuelu Zhu,Shuang-mei Zou,Liming Jiang,Yu Tang,Jianwei Liang,Yongjun Sun,Zhichao Jiang,Wang Qu,Ying Li,Aiping Zhou +12 more
TL;DR: In this paper , the authors evaluated the efficacy and safety of triplet chemotherapy with mFOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan) in LARC.
Dynamic alteration and prognostic significance of tumor‐associated CD68+ and CD68+PD‐L1− macrophages in muscle‐invasive bladder cancer treated with neoadjuvant chemotherapy
Jie Wu,Ruiyang Xie,Li-Hui Wei,Chuanzhen Cao,Bingqing Shang,You-Yan Guan,Hongzhe Shi,Wang Qu,Yun Li,Jing Jiang,Shan Zheng,Ai-Ping Zhou,Xiaofeng Zhou,Jianzhong Shou,Xingang Bi +14 more
TL;DR: CD68+ and CD68+ PD-L1- TAMs infiltration levels decreased significantly after NAC and pre-treatment TAM infiltration levels were independent prognostic factors for MIBC patients, while there was no sufficient evidence demonstrating that pre- treatment TILs or TAMs could predict response to NAC in MIBC Patients.
1
Treatment modalities of regorafenib and survival in metastatic colorectal (mCRC) patients: A real-world multicenter retrospective study.
Wang Qu,Zi Wei Liu,Liangjun Zhu,Xiaobing Chen,Bo Liu,Yun-Bo Zhao,Hao Yan,Xiujuan Qu,Shengmian Li,Aimin Zang,Zhichao Jiang,Yongjun Sun,Aiping Zhou +12 more
TL;DR: Wang et al. as mentioned in this paper conducted a retrospective study of patients with refractory mCRC receiving at least one cycle of regorafenib as the third or higher line treatment from August 2017 to June 2020 in China.
1